These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11442487)

  • 21. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
    Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
    Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
    Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective comparison of cyclophosphamide plus antithymocyte globulin with cyclophosphamide plus busulfan as the conditioning regimen for severe aplastic anemia.
    Ommati LV; Rodrigues CA; Silva AR; Silva LP; Chaufaille ML; Oliveira JS
    Braz J Med Biol Res; 2009 Mar; 42(3):244-50. PubMed ID: 19287903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia.
    Azuma E; Kojima S; Kato K; Matsuyama T; Yamada Y; Kondo N; Sawada H; Hanada M; Shibata T; Tabata N; Watanabe M; Shimono Y; Deguchi T; Umemoto M; Higashikawa M; Kawasaki H; Komada Y; Sakurai M
    Bone Marrow Transplant; 1997 Jun; 19(11):1085-7. PubMed ID: 9193750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.
    Kim H; Lee JH; Joo YD; Bae SH; Hyun MS; Lee JH; Kim DY; Lee WS; Ryoo HM; Kim MK; Park JH; Lee KH;
    Ann Hematol; 2012 Sep; 91(9):1459-69. PubMed ID: 22526363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.
    Raida L; Tucek P; Faber E; Vondrakova J; Rusinakova Z; Skoumalova I; Hubacek J; Jarosova M; Katrincsakova B; Pikalova Z; Kurfurst P; Indrak K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Dec; 155(4):327-32. PubMed ID: 22336644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.
    Ladenstein R; Peters C; Minkov M; Emminger-Schmidmeier W; Mann G; Höcker P; Hawliczek R; Rosenmayr A; Fink FM; Niederwieser D; Gadner H
    Klin Padiatr; 1997; 209(4):201-8. PubMed ID: 9293451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic hematopoietic stem cell transplantation for children with severe aplastic anemia.
    Hutspardol S; Sirachainan N; Anurathapan U; Pakakasama S; Songdej D; Chuansumrit A; Sirireung S; Panthangkool W; Hongeng S
    J Med Assoc Thai; 2013 Jan; 96 Suppl 1():S18-24. PubMed ID: 23724451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Rubio MT; Labopin M; Blaise D; Socié G; Contreras RR; Chevallier P; Sanz MA; Vigouroux S; Huynh A; Shimoni A; Bulabois CE; Caminos N; López-Corral L; Nagler A; Mohty M
    Haematologica; 2015 May; 100(5):683-9. PubMed ID: 25769546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin.
    Yu ZP; Ding JH; Wu F; Liu J; Wang J; Cheng J; Zhao G
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):593-9. PubMed ID: 21846461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
    Bertz H; Potthoff K; Mertelsmann R; Finke J
    Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia.
    Zanis-Neto J; Flowers ME; Medeiros CR; Bitencourt MA; Bonfim CM; Setúbal DC; Funke V; Sanders J; Deeg HJ; Kiem HP; Martin P; Leisenring W; Storb R; Pasquini R
    Br J Haematol; 2005 Jul; 130(1):99-106. PubMed ID: 15982351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.
    Horan JT; Haight A; Dioguardi JL; Brown C; Grizzle A; Shelman C; Kanter J; Hale G; Nieder M; Benton M; Kasow KA; Abraham A; Chiang KY
    Biol Blood Marrow Transplant; 2015 May; 21(5):900-5. PubMed ID: 25617808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
    Bornhäuser M; Thiede C; Schuler U; Platzbecker U; Freiberg-Richter J; Helwig A; Plettig R; Röllig C; Naumann R; Kroschinsky F; Neubauer A; Ehninger G
    Bone Marrow Transplant; 2000 Jul; 26(2):119-25. PubMed ID: 10918420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of two doses of anti-T lymphocyte globulin-Fresenius given after full-match sibling stem cell transplantation in acute myeloblastic leukemia patients who underwent myeloablative fludarabine/busulfan conditioning.
    Boga C; Yeral M; Gereklioglu C; Asma S; Maytalman E; Aytan P; Kozanoglu I; Sariturk C; Ozdogu H
    Hematol Oncol Stem Cell Ther; 2018 Sep; 11(3):149-157. PubMed ID: 29474820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.